TROY, Mich., Feb. 6 /PRNewswire-FirstCall/ -- Somanetics Corporation today announced that Nasdaq has approved its application to move its listing from The Nasdaq Capital Market(R) (formerly known as The Nasdaq SmallCap Market) to The Nasdaq National Market(R). Somanetics' common shares will begin trading on The Nasdaq National Market on Tuesday, February 7, 2006, and the Company will continue to trade under the symbol "SMTS."
About Somanetics
Somanetics develops, manufactures and markets the INVOS System, a non-invasive patient monitoring system that continuously measures changes in the blood oxygen levels in the brain. Surgeons, anesthesiologists and other medical professionals can use the information provided by the INVOS System, in conjunction with other available information, to identify brain oxygen imbalances and take necessary corrective action, potentially improving patient outcomes and reduce the costs of care. In November 2005, Somanetics received 510(k) clearance to market the INVOS System to monitor changes in blood oxygen saturation elsewhere in the body in somatic, or skeletal muscle, tissue in patients with or at risk for restricted blood flow. Somanetics also develops and markets the CorRestore System, which includes a cardiac implant, for use in cardiac repair and reconstruction, including heart surgeries called surgical ventricular restoration, or SVR. The CorRestore System was developed with the intent to make SVR easier for the surgeon and to standardize the operation. Somanetics supports its customers through a direct U.S. sales force and clinical education team. Globally, Edwards Lifesciences represents INVOS System products in Japan, and Tyco Healthcare markets INVOS System products in Europe, Canada, the Middle East and Africa. For more information visit http://www.somanetics.com .
Safe-Harbor Statement
Except for historical information contained in this press release, the matters discussed in this news release, including statements about future plans, goals and other events which have not yet occurred, are "forward- looking statements," the accuracy of which is necessarily subject to risks and uncertainties. Actual results may differ significantly from results discussed in the forward-looking statements. Actual results may be affected by factors set forth from time to time in Somanetics' Securities and Exchange Commission filings, including Somanetics' 2005 Annual Report on Form 10-K filed on January 31, 2006.
Somanetics CorporationCONTACT: Mary Ann Victor, Vice President and Chief Administrative Officerof Somanetics Corporation, +1-248-689-3050, Extension 204, Fax:+1-248-689-4272
Web site: http://www.somanetics.com/
